2024
Hypofractionated vs Conventionally Fractionated Postmastectomy Radiation After Implant-Based Reconstruction
Wong J, Uno H, Tramontano A, Fisher L, Pellegrini C, Abel G, Burstein H, Chun Y, King T, Schrag D, Winer E, Bellon J, Cheney M, Hardenbergh P, Ho A, Horst K, Kim J, Leonard K, Moran M, Park C, Recht A, Soto D, Shiloh R, Stinson S, Snyder K, Taghian A, Warren L, Wright J, Punglia R. Hypofractionated vs Conventionally Fractionated Postmastectomy Radiation After Implant-Based Reconstruction. JAMA Oncology 2024, 10 PMID: 39115975, PMCID: PMC11310844, DOI: 10.1001/jamaoncol.2024.2652.Peer-Reviewed Original ResearchFunctional Assessment of Cancer Therapy-BreastPhysical well-beingPostmastectomy radiation therapyImplant-based reconstructionConventional fractionationStudy armsPhysical well-being scoresUS cancer centersLocal-regional disease controlImprove quality of lifeQuality of lifeAs-treated cohortChest wall doseHigher adverse eventsToxic effectsMain OutcomesRandomized clinical trialsPWB scoreUnpaid timePostmastectomy radiationImplant reconstructionRadiation therapyTreatment breaksImplant-basedImprovement changes
2022
Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer
Bellon JR, Tayob N, Yang DD, Tralins J, Dang CT, Isakoff SJ, DeMeo M, Burstein HJ, Partridge AH, Winer EP, Krop IE, Tolaney SM. Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer. International Journal Of Radiation Oncology • Biology • Physics 2022, 113: 117-124. PMID: 34990776, DOI: 10.1016/j.ijrobp.2021.12.173.Peer-Reviewed Original ResearchConceptsHER2-positive breast cancerBreast-conserving surgeryStage I HER2-positive breast cancerT-DM1 armBreast radiation therapyT-DM1Radiation therapySkin toxicityBreast cancerBCS patientsWBRT patientsInvasive disease-free survival eventsDisease-free survival eventsInvasive disease-free survivalHuman epidermal growth factor receptor 2Phase II Randomized TrialWhole breast radiation therapyEpidermal growth factor receptor 2Adjuvant T-DM1Adjuvant trastuzumab emtansineEfficacy of HER2RT-related toxicityWeeks of therapyAcute skin toxicityAnti-HER2 therapy
2021
Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033), a Phase II Randomized Trial of Adjuvant T-DM1 vs. TH in Women With Stage I HER2 Positive Breast Cancer
Bellon J, Tayob N, Burstein H, Partridge A, Demeo M, Tralins J, Yang D, Dang C, Isakoff S, Yardley D, Valero V, Winer E, Krop I, Tolaney S. Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033), a Phase II Randomized Trial of Adjuvant T-DM1 vs. TH in Women With Stage I HER2 Positive Breast Cancer. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: s34. DOI: 10.1016/j.ijrobp.2021.07.103.Peer-Reviewed Original ResearchT-DM1 armBreast conserving surgeryPartial breast irradiationT-DM1Radiation therapyBreast cancerLocal recurrenceSkin toxicityGrade 2 acute skin toxicityProspective randomized phase II studyGrade 3 skin toxicityHormone receptor-positive diseaseRandomized phase II studyPhase II Randomized TrialAdjuvant T-DM1Conclusions Radiation therapyGrade 2 pneumonitisGrade 3 pneumonitisIpsilateral rib fracturesPhase II studyReceptor-positive diseaseWeeks of therapyAcute skin toxicityAnti-HER2 therapyNodal radiation therapyA Phase 1 Dose-Escalation Trial of Radiation Therapy and Concurrent Cisplatin for Stage II and III Triple-Negative Breast Cancer
Bellon JR, Chen YH, Rees R, Taghian AG, Wong JS, Punglia RS, Shiloh RY, Warren LEG, Krishnan MS, Phillips J, Pretz J, Jimenez R, Macausland S, Pashtan I, Andrews C, Isakoff SJ, Winer EP, Tolaney SM. A Phase 1 Dose-Escalation Trial of Radiation Therapy and Concurrent Cisplatin for Stage II and III Triple-Negative Breast Cancer. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: 45-52. PMID: 33713742, DOI: 10.1016/j.ijrobp.2021.03.002.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerBreast-conserving therapyDose-limiting toxicityBCT cohortRadiation therapyConcurrent cisplatinMastectomy cohortBreast cancerEarly-stage triple-negative breast cancerThree-year disease-free survivalPhase 1 dose-escalation trialStage IILocal-regional recurrence ratePhase 2 doseAdjuvant radiation therapyDisease-free survivalDose-escalation trialPhase 1b trialDose of cisplatinHER2-positive tumorsEligible patientsUrinary infectionAdditional patientsDose escalationRecurrence rate
2020
A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer
Barroso-Sousa R, Krop IE, Trippa L, Tan-Wasielewski Z, Li T, Osmani W, Andrews C, Dillon D, Richardson ET, Pastorello RG, Winer EP, Mittendorf EA, Bellon JR, Schoenfeld JD, Tolaney SM. A Phase II Study of Pembrolizumab in Combination With Palliative Radiotherapy for Hormone Receptor-positive Metastatic Breast Cancer. Clinical Breast Cancer 2020, 20: 238-245. PMID: 32113750, DOI: 10.1016/j.clbc.2020.01.012.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalBiomarkers, TumorBreastBreast NeoplasmsCarcinoma, Ductal, BreastChemoradiotherapyDrug Administration ScheduleFemaleHumansInfusions, IntravenousMiddle AgedPalliative CareProgrammed Cell Death 1 ReceptorProgression-Free SurvivalReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneResponse Evaluation Criteria in Solid TumorsConceptsMetastatic breast cancerHormone receptor-positive metastatic breast cancerProgression-free survivalRadiation therapyObjective responseOverall survivalBreast cancerResponse rateMedian progression-free survivalCause adverse eventsGrade 3 eventsMedian prior linesMedian overall survivalObjective response ratePalliative radiation therapyPhase II studyTumor-infiltrating lymphocytesLymph node lesionsOverall response rateEpidermal growth factor receptorEligible patientsExploratory endpointsGrowth factor receptorPalliative radiotherapyPrimary endpoint
2019
A Prospective Phase I trial of Concurrent Cisplatin (CIS) and Radiation Therapy (RT) in Women with Stage II and III Triple-negative Breast Cancer (TNBC)
Bellon J, Chen Y, Rees R, Taghian A, Wong J, Punglia R, Shiloh R, Krishnan M, Andrews C, Isakoff S, Winer E, Tolaney S. A Prospective Phase I trial of Concurrent Cisplatin (CIS) and Radiation Therapy (RT) in Women with Stage II and III Triple-negative Breast Cancer (TNBC). International Journal Of Radiation Oncology • Biology • Physics 2019, 105: s43. DOI: 10.1016/j.ijrobp.2019.06.466.Peer-Reviewed Original ResearchLocal–regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial)
Bellon JR, Guo H, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Hudis CA, Krop I, Burstein HJ, Winer EP, Tolaney SM. Local–regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). Breast Cancer Research And Treatment 2019, 176: 303-310. PMID: 31004299, DOI: 10.1007/s10549-019-05238-4.Peer-Reviewed Original ResearchConceptsHER2-positive breast cancerLocal-regional recurrenceDisease-free survivalEffective anti-HER2 therapyLRR-free survivalAnti-HER2 therapyBreast-conserving surgeryBreast cancerRadiation therapySystemic therapyHormone receptor-positive tumorsProspective multi-institutional studyHER2-negative diseaseHER2-positive diseaseNegative axillary nodesEffective systemic therapyProspective multicenter trialEarly-stage patientsKaplan-Meier methodReceptor-positive tumorsHER2-positive tumorsMulti-institutional studyFuture investigational effortsAdjuvant trastuzumabProtocol therapy
2013
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn H, members P, Albain K, André F, Bergh J, Bonnefoi H, Bretel-Morales D, Burstein H, Cardoso F, Castiglione-Gertsch M, Coates A, Colleoni M, Costa A, Curigliano G, Davidson N, Di Leo A, Ejlertsen B, Forbes J, Gelber R, Gnant M, Goldhirsch A, Goodwin P, Goss P, Harris J, Hayes D, Hudis C, Ingle J, Jassem J, Jiang Z, Karlsson P, Loibl S, Morrow M, Namer M, Osborne C, Partridge A, Penault-Llorca F, Perou C, Piccart-Gebhart M, Pritchard K, Rutgers E, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Thürlimann B, Toi M, Tutt A, Untch M, Viale G, Watanabe T, Wilcken N, Winer E, Wood W. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals Of Oncology 2013, 24: 2206-2223. PMID: 23917950, PMCID: PMC3755334, DOI: 10.1093/annonc/mdt303.Peer-Reviewed Original ResearchConceptsEarly breast cancerLuminal diseaseBreast cancerHuman epidermal growth factor receptor 2 (HER2) oncogeneSt Gallen International Expert ConsensusBroad treatment recommendationsReproducible prognostic informationSystemic adjuvant therapyClinico-pathological factorsAnnals of OncologyMolecular assaysSubstantial new evidenceTreatment of womenInternational expert consensusPrimary therapyAdjuvant therapyExtensive surgeryDisease extentRegional therapyPatient preferencesPrognostic informationTreatment recommendationsChemotherapy decisionsRadiation therapyClinical considerationsLumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343
Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, Muss HB, Smith BL, Hudis CA, Winer EP, Wood WC. Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343. Journal Of Clinical Oncology 2013, 31: 2382-2387. PMID: 23690420, PMCID: PMC3691356, DOI: 10.1200/jco.2012.45.2615.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic Agents, HormonalBiomarkers, TumorBreast NeoplasmsFemaleFollow-Up StudiesHumansKaplan-Meier EstimateMastectomy, SegmentalNeoplasm Recurrence, LocalNeoplasm StagingOdds RatioRadiotherapy, AdjuvantReceptors, EstrogenTamoxifenTime FactorsTreatment OutcomeConceptsBreast cancer-specific survivalEarly-stage breast cancerCancer-specific survivalOverall survivalBreast cancerRadiation therapyRegional recurrenceDistant metastasisER-positive early-stage breast cancerDistant disease-free survivalWomen age 70 yearsEstrogen receptor-positive breast carcinomasFrequency of mastectomyTen-year OSAdjuvant radiation therapyPrimary end pointDisease-free survivalEarly breast cancerAge 70 yearsBreast-conserving surgeryBreast preservationCALGB 9343Locoregional recurrenceTAM groupLocal recurrence
2011
Can Axillary Node Dissection Be Omitted in a Subset of Patients with Low Local and Regional Failure Rates?
Barkley C, Burstein H, Smith B, Bellon J, Wong J, Gadd M, Taghian A, Winer E, Iglehart JD, Harris J, Golshan M. Can Axillary Node Dissection Be Omitted in a Subset of Patients with Low Local and Regional Failure Rates? The Breast Journal 2011, 18: 23-27. PMID: 22017599, DOI: 10.1111/j.1524-4741.2011.01178.x.Peer-Reviewed Original ResearchConceptsPositive sentinel lymph nodesSentinel lymph node biopsySentinel lymph nodesAxillary node dissectionCompletion axillary node dissectionLow-risk patient populationAdjuvant treatment patternMedian patient agePercent of patientsLymph node biopsyStandard of careNodal radiationNode dissectionMicrometastatic diseaseNode biopsyLymph nodesPatient ageTreatment patternsPatient populationBreast cancerClinical dataRadiation therapyPatientsDiseaseMacrometastasis
2010
Phase I study of lapatinib (L) in combination with whole-brain radiation therapy (WBRT) in patients (pts) with brain metastases from HER2-positive breast cancer.
Lin N, Ramakrishna N, Younger W, Storniolo A, Come S, Gelman R, Eisenberg E, Winer E. Phase I study of lapatinib (L) in combination with whole-brain radiation therapy (WBRT) in patients (pts) with brain metastases from HER2-positive breast cancer. Journal Of Clinical Oncology 2010, 28: 1154-1154. DOI: 10.1200/jco.2010.28.15_suppl.1154.Peer-Reviewed Original Research
2007
Clinical Cancer Advances 2007: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology
Gralow J, Ozols RF, Bajorin DF, Cheson BD, Sandler HM, Winer EP, Bonner J, Demetri GD, Curran W, Ganz PA, Kramer BS, Kris MG, Markman M, Mayer RJ, Raghavan D, Ramsey S, Reaman GH, Sawaya R, Schuchter LM, Sweetenham JW, Vahdat LT, Davidson NE, Schilsky RL, Lichter AS. Clinical Cancer Advances 2007: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology. Journal Of Clinical Oncology 2007, 26: 313-325. PMID: 18086794, DOI: 10.1200/jco.2007.15.4088.Peer-Reviewed Original ResearchConceptsNational Cancer InstituteClinical Trials Cooperative GroupsClinical OncologyCancer researchAmerican SocietyCancer treatmentScreening—A ReportHormone replacement therapyBreast cancer incidenceNumber of patientsBreast cancer screeningClinical cancer researchReplacement therapyCancer research fundingHuman papillomavirusCancer careCancer patientsCancer screeningLung cancerNeck cancerCancer incidenceClinical trialsKidney cancerLiver cancerRadiation therapy
2006
Quality of life (QOL) companion to CALGB 9840: A phase III study of paclitaxel (P) via weekly 1 hour (hr) versus standard 3 hour infusion every 3 weeks with trastuzumab in the treatment of patients with/without HER-2/neu-overexpressing metastatic breast cancer
Naughton M, Gu L, Wang X, Seidman A, Winer E, Kornblith A. Quality of life (QOL) companion to CALGB 9840: A phase III study of paclitaxel (P) via weekly 1 hour (hr) versus standard 3 hour infusion every 3 weeks with trastuzumab in the treatment of patients with/without HER-2/neu-overexpressing metastatic breast cancer. Journal Of Clinical Oncology 2006, 24: 674-674. DOI: 10.1200/jco.2006.24.18_suppl.674.Peer-Reviewed Original ResearchNegative patientsQOL differencesGreater efficacyMain trial resultsPrior radiation therapyMetastatic breast cancerPhase III studyTreatment of patientsMain outcome measuresEORTC-C30Prior chemotherapyBreast symptomsIII studyPerformance statusPatient ageHour infusionTreatment armsBreast moduleGlobal QoLCancer symptomsBreast cancerClinical dataQoL dataOutcome measuresRadiation therapy
2005
Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer
Burstein HJ, Bellon JR, Galper S, Lu HM, Kuter I, Taghian AG, Wong J, Gelman R, Bunnell CA, Parker LM, Garber JE, Winer EP, Harris JR, Powell SN. Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer. International Journal Of Radiation Oncology • Biology • Physics 2005, 64: 496-504. PMID: 16243442, DOI: 10.1016/j.ijrobp.2005.07.975.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantCyclophosphamideDoxorubicinDrug Administration ScheduleFeasibility StudiesFemaleHumansPaclitaxelProspective StudiesRadiation PneumonitisRadiation-Sensitizing AgentsRadiotherapy DosageRadiotherapy, AdjuvantConceptsRadiation therapyBreast cancerAdjuvant doxorubicinConcurrent paclitaxelWeekly paclitaxelAC chemotherapyConcurrent radiationConcurrent treatmentGrade 2 radiation pneumonitisStage IIEarly-stage breast cancerAdjuvant AC chemotherapyDefinitive breast surgeryOperable stage IIWeekly paclitaxel treatmentConcurrent radiation therapyDose-limiting toxicityProtocol-based treatmentAdjuvant chemotherapyPaclitaxel scheduleSteroid therapyCyclophosphamide chemotherapyRadiation pneumonitisPulmonary injuryRadiation dermatitisPrognosis after local recurrence after conservative surgery and radiation for early-stage breast cancer
Galper S, Blood E, Gelman R, Abner A, Recht A, Kohli A, Wong JS, Smith D, Bellon J, Connolly J, Schnitt S, Winer E, Silver B, Harris JR. Prognosis after local recurrence after conservative surgery and radiation for early-stage breast cancer. International Journal Of Radiation Oncology • Biology • Physics 2005, 61: 348-357. PMID: 15667952, DOI: 10.1016/j.ijrobp.2004.06.011.Peer-Reviewed Original ResearchConceptsLocal recurrenceConservative surgeryBreast cancerDistant metastasisInitial diagnosisRadiation therapyEarly-stage invasive breast cancerDistant disease-free survivalEarly-stage breast cancerClinical stage IDisease-free survivalFinal study populationInvasive breast cancerLong-term prognosisProportional hazards modelNonbreast malignanciesActuarial freedomMedian followDistant failureSecond malignanciesIpsilateral breastLocal therapyRegional nodalMedian timeStudy population
2004
Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer
Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B, Wheeler J, Champion LA, Smith TJ, Smith BL, Shapiro C, Muss HB, Winer E, Hudis C, Wood W, Sugarbaker D, Henderson IC, Norton L. Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer. New England Journal Of Medicine 2004, 351: 971-977. PMID: 15342805, DOI: 10.1056/nejmoa040587.Peer-Reviewed Original ResearchConceptsWomen 70 yearsEarly breast cancerBreast cancerOverall survivalRegional recurrenceDistant metastasisRadiation therapyEstrogen receptor-positive breast carcinomasFrequency of mastectomyClinical stage IPrimary end pointFive-year ratesRate of mastectomyPositive breast cancerYears of ageSignificant differencesAdjuvant therapyAdverse eventsSpecific survivalLocal recurrenceCosmetic resultsOnly significant differenceBreast carcinomaLumpectomyStage I